Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Serum sclerostin, but not DKK1, increases in more advanced stages of CKD and associates with PTH, phosphate, and 1,25(OH)2 vitamin D concentrations.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were recruited from an ongoing observational study at the University Hospitals Leuven, Belgium, investigating uremic toxicity and bone and mineral metabolism in CKD patients ().

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD

Study design awaiting verification · PLoS ONE · 2017

Original publication title

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD

Geert J. Behets; Liesbeth Viaene; Björn Meijers; Frank Blocki; Vincent M. Brandenburg; Anja Verhulst; Patrick C. D’Haese; Pieter Evenepoel

© 2017 Behets et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In CKD, serum levels of the Wnt inhibitors DKK1 and sclerostin are unrelated, indicating different sites of origin and/ or different regulatory mechanisms. Sclerostin, as opposed to DKK1, may qualify as a biomarker of CKD-MBD, particularly in dialysis patients. DKK1 serum levels, remarkably, correlate almost uniquely with blood platelet counts.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Mounting evidence indicates that a disturbed Wnt: β-catenin signaling may be involved in the pathogenesis of chronic kidney disease-mineral and bone and mineral disorder (CKD-MBD). Data on the impact of CKD on circulating levels of the Wnt antagonists sclerostin and Dickkopf related protein 1 (DKK1) and the relationship with laboratory parameters of CKD-MBD are incomplete.

Source: Introduction

Abstract: What methods does the paper describe?

We analyzed serum sclerostin and DKK1 in 308 patients across the stages of chronic kidney disease (kDOQI stage 1 to 2 n = 41; CKD stage 3 n = 54; CKD stage 4 to 5 n = 54; hemodialysis n = 100; peritoneal dialysis n = 59) as well as in 49 healthy controls. We investigated associations with demographics, renal function, parameters of mineral metabolism including 25(OH) vitamin D, 1,25(OH)2 vitamin D, biointact fibroblast growth factor 23 (FGF23), and parathyroid hormone (PTH), and bone turnover markers.

Source: Methods

Abstract: Results

Serum sclerostin, but not DKK1, increases in more advanced stages of CKD and associates with PTH, phosphate, and 1,25(OH)2 vitamin D concentrations. Bone turnover markers are highest in hemodialysis patients presenting the combination of high PTH with low sclerostin level. Serum DKK1 levels are lower in CKD patients than in controls and are not associated with laboratory parameters of mineral metabolism. Interestingly, a direct association between DKK1 and platelet count was observed.

Source: Results

Abstract: Conclusion

In CKD, serum levels of the Wnt inhibitors DKK1 and sclerostin are unrelated, indicating different sites of origin and/ or different regulatory mechanisms. Sclerostin, as opposed to DKK1, may qualify as a biomarker of CKD-MBD, particularly in dialysis patients. DKK1 serum levels, remarkably, correlate almost uniquely with blood platelet counts.

Source: Conclusion
Authors’ abstract

Introduction

Mounting evidence indicates that a disturbed Wnt: β-catenin signaling may be involved in the pathogenesis of chronic kidney disease-mineral and bone and mineral disorder (CKD-MBD). Data on the impact of CKD on circulating levels of the Wnt antagonists sclerostin and Dickkopf related protein 1 (DKK1) and the relationship with laboratory parameters of CKD-MBD are incomplete.

Methods

We analyzed serum sclerostin and DKK1 in 308 patients across the stages of chronic kidney disease (kDOQI stage 1 to 2 n = 41; CKD stage 3 n = 54; CKD stage 4 to 5 n = 54; hemodialysis n = 100; peritoneal dialysis n = 59) as well as in 49 healthy controls. We investigated associations with demographics, renal function, parameters of mineral metabolism including 25(OH) vitamin D, 1,25(OH)2 vitamin D, biointact fibroblast growth factor 23 (FGF23), and parathyroid hormone (PTH), and bone turnover markers.

Results

Serum sclerostin, but not DKK1, increases in more advanced stages of CKD and associates with PTH, phosphate, and 1,25(OH)2 vitamin D concentrations. Bone turnover markers are highest in hemodialysis patients presenting the combination of high PTH with low sclerostin level. Serum DKK1 levels are lower in CKD patients than in controls and are not associated with laboratory parameters of mineral metabolism. Interestingly, a direct association between DKK1 and platelet count was observed.

Conclusion

In CKD, serum levels of the Wnt inhibitors DKK1 and sclerostin are unrelated, indicating different sites of origin and/ or different regulatory mechanisms. Sclerostin, as opposed to DKK1, may qualify as a biomarker of CKD-MBD, particularly in dialysis patients. DKK1 serum levels, remarkably, correlate almost uniquely with blood platelet counts.

Publication and source details

Original title: Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD

Geert J. Behets; Liesbeth Viaene; Björn Meijers; Frank Blocki; Vincent M. Brandenburg; Anja Verhulst; Patrick C. D’Haese; Pieter Evenepoel

PLoS ONE · 2017

Competing Interests: The authors of this manuscript have read the journal's policy and have the following competing interests: FB is an employee of Diasorin Inc. The funder provided support in the form of salaries for author FB and supplied research materials for the current study. The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The commercial affiliation does not alter the authors' adherence to all PLOS ONE policies on sharing data and material.

  • Conceptualization: VMB PCD PE.

  • Formal analysis: GJB LV BM PE.

  • Funding acquisition: FB PCD PE.

  • Investigation: GJB LV BM AV.

  • Methodology: GJB LV FB PCD PE.

  • Project administration: GJB PCD PE.

  • Resources: FB VMB PCD PE.

  • Supervision: PCD PE.

  • Validation: GJB BM AV.

  • Visualization: GJB PE.

  • Writing: original draft: GJB PCD PE.

  • Writing: review & editing: GJB VMB AV PCD PE.

* E-mail: Pieter.Evenepoel@uzleuven.be
© 2017 Behets et al2017Behets et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Diasorin IncFranck BlockiDiasorin SAPPatrick C. D'HaeseFB is an employee of Diasorin Inc. The funder provided support in the form of salaries for author FB and also supplied research materials for the current study. PCD has received previous research grants from Diasorin SAP.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T08:03:05.913540+00:00

DOI: 10.1371/journal.pone.0176411 · PMC5426702